Optimizing Histologic Entry Criteria for Clinical Trials in Celiac Disease Involving Gluten Challenge
Clinical Gastroenterology and Hepatology · 2026-05
DOI: 10.1016/j.cgh.2026.04.031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-05. Verfasst von Benjamin Lebwohl und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Celiac Disease Center, Columbia University Irving Medical Center, New York, New York. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben. Gefördert von: National Institutes of Health, Johnson and Johnson, Immunic.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Medicine, Celiac Disease Center, Columbia University Irving Medical Center, New York, New York.
- Chugai Pharma, Tokyo, Japan; Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. Electronic address: dleffler@bidmc.harvard.edu.
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Förderung
- National Institutes of Health
- Johnson and Johnson
- Immunic
- Bristol-Myers Squibb
- Oberkotter Foundation
Zitieren
APA
Lebwohl, B., Leffler, D. A., & Murray, J. A. (2026). Optimizing Histologic Entry Criteria for Clinical Trials in Celiac Disease Involving Gluten Challenge. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2026.04.031
Vancouver
Lebwohl B, Leffler DA, Murray JA. Optimizing Histologic Entry Criteria for Clinical Trials in Celiac Disease Involving Gluten Challenge. Clinical Gastroenterology and Hepatology. 2026. doi:10.1016/j.cgh.2026.04.031
BibTeX
@article{Lebwohl2026,
author = {Lebwohl, Benjamin and Leffler, Daniel A and Murray, Joseph A},
title = {Optimizing Histologic Entry Criteria for Clinical Trials in Celiac Disease Involving Gluten Challenge},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
doi = {10.1016/j.cgh.2026.04.031}
}
EUVIMED